May 04, 2022
PROTAC Design
- boc.protac 1
- 1BOC Sciences
- PROTAC
External link: https://ptc.bocsci.com/services/protac-design-services.html
Protocol Citation: boc.protac 2022. PROTAC Design. protocols.io https://dx.doi.org/10.17504/protocols.io.n92ldz72nv5b/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it’s working
Created: May 04, 2022
Last Modified: May 04, 2022
Protocol Integer ID: 61935
Keywords: ubiquitin proteasome pathway, proteasome for degradation, protac molecular discovery package services to customer, special protein degradation technology, natural protein degradation pathway, target proteins through the protein destruction mechanism, protac molecule, protein degradation, natural protein degradation pathway in cell, targeting molecular drug discovery, protein destruction mechanism, target protein, specific protein, protein, molecular drug discovery, molecular discovery package service, activity of target protein, e3 ubiquitination ligase, stop proteolysi, protac, traditional small molecule inhibitor, new drug discovery goal, proteasome, targeted chimera, drug discovery, protac design protac, intracellular proteins with abnormal structure, intracellular protein, protac design, service provider in drug discovery, inhibitor, enzyme, polyubiquitin
Abstract
PROTAC (protein degradation targeted chimera) is a special protein degradation technology, which uses ubiquitin proteasome pathway, a natural protein degradation pathway in cells, to remove specific proteins that need to be degraded. A PROTAC molecule consists of two key domains: the domain that specifically binds to the target protein that needs to be degraded, and the domain that binds to the E3 ubiquitination ligase, which is linked by a specific linker. Unlike traditional small molecule inhibitors, which can only regulate the activity of target proteins, PROTAC can directly degrade target proteins through the protein destruction mechanism of cells themselves. Intracellular proteins with abnormal structure or function are labeled with polyubiquitin by a series of enzymes, which are then transferred to the proteasome for degradation.
As a leading service provider in drug discovery and research, BOC Sciences is fully capable and committed to providing one-stop proteolysis targeting molecular drug discovery based on chimeric (PROTAC®). This has become a promising strategy in the field of drug discovery. With a comprehensive and advanced platform, we provide PROTAC molecular discovery package services to customers around the world to meet new drug discovery goals. This includes a variety of services that cover the entire process.